Hepatic Insulin Resistance Following Chronic Activation of the CREB Coactivator CRTC2*

Meghan F. Hogan§5, Kim Ravnskjaer†§, Shigenobu Matsumura‡§, Mark O. Huising**§, Rebecca L. Hull†, Steven E. Kahn§, and Marc Montminy†

From the§5Peptide Biology Laboratories, Salk Institute for Biological Studies, La Jolla, California 92037, †Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington 98108, ‡Division of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark, §Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Oiwake-cho, Kitashirakawa, Sakyo-ku, Kyoto, 606-8502, Japan, and **Department of Physiology and Membrane Biology, School of Medicine, University of California, Davis, California 95616

Background: Loss of CRTC2 improves insulin sensitivity, but it is unknown if chronic CRTC2 activity causes hepatic insulin resistance.

Results: Liver expression of constitutively active CRTC2 increased hepatic glucose production, despite compensatory increases in FOXO1 phosphorylation.

Conclusion: Persistent increases in CRTC2 activation promote hepatic insulin resistance.

Significance: Disrupting CREB signaling in liver could provide therapeutic benefit against insulin resistance.

Under fasting conditions, increases in circulating concentrations of glucagon maintain glucose homeostasis via the induction of hepatic gluconeogenesis. Triggering of the cAMP pathway in hepatocytes stimulates the gluconeogenic program via the PKA-mediated phosphorylation of CREB and dephosphorylation of the cAMP-regulated CREB coactivators CRTC2 and CRTC3. In parallel, decreases in circulating insulin also increase gluconeogenic gene expression via the de-phosphorylation and activation of the forkhead transcription factor FOXO1. Hepatic gluconeogenesis is increased in insulin resistance where it contributes to the attendant hyperglycemia. Whether selective activation of the hepatic CREB/CRTC pathway is sufficient to trigger metabolic changes in other tissues is unclear, however. Modest hepatic expression of a phosphorylation-defective and therefore constitutively active CRTC2S171,275A protein increased gluconeogenic gene expression under fasting as well as feeding conditions. Circulating glucose concentrations were constitutively elevated in CRTC2S171,275A-expressing mice, leading to compensatory increases in circulating insulin concentrations that enhance FOXO1 phosphorylation. Despite accompanying decreases in FOXO1 activity, hepatic gluconeogenic gene expression remained elevated in CRTC2S171,275A mice, demonstrating that chronic increases in CRTC2 activity in the liver are indeed sufficient to promote hepatic insulin resistance and to disrupt glucose homeostasis.

In unaffected and appropriately regulated systems, blood glucose levels remain remarkably constant, despite alternating periods of caloric abundance and scarcity. This level of control is preserved by balancing hepatic glucose production (gluconeogenesis and glycogenolysis) during fasting with the glucose uptake into peripheral tissues during feeding. The transition from a high-risk state to type 2 diabetes is marked by insulin resistance, and an inability for insulin to inhibit hepatic gluconeogenesis, resulting in elevated fasting blood glucose (1–4).

Under fasting conditions, increases in glucagon upregulate the gluconeogenic program by triggering the cAMP pathway (5) and stimulating the protein kinase A (PKA)2-mediated phosphorylation of cAMP response element-binding protein (CREB). Serine 133 phosphorylation of CREB in turn promotes recruitment of the histone acetyltransferase paralogs CREB-binding protein (CBP) and P300 (6, 7).

Superimposed on effects of the CREB:CBP pathway, cAMP also stimulates hepatic gene expression in the liver via the induction of the cAMP-regulated CREB Coactivators (CRTC). Under basal conditions, CRTC are phosphorylated by salt-inducible kinases (SIKs) and sequestered in the cytoplasm by association with 14–3–3 proteins (8). Triggering of the cAMP pathway promotes the inhibitory phosphorylation of salt-inducible kinases (SIKs) by PKA, leading to the dephosphorylation and translocation of CRTC to the nucleus, where they associate with relevant target genes via an interaction with CREB (8–13).

The importance of the CREB:CRTC pathway in hepatic gluconeogenesis is supported by studies in which acute RNAi-me-
Activation of CRTC2 Causes Hepatic Insulin Resistance

diated knockdown of CRTC2 in liver decreases gluconeogenic gene expression as well as circulating glucose concentrations (9, 14). Cultured hepatocytes from CRTC2 knock-out mice also exhibit decreases in glucose production (12, 15), although these effects are more modest due to compensation by CRTC3 (16).

Recognizing the importance of the CREB/CRTC2 pathway in the fasting adaptation, we wondered whether modest expression of an active form of CRTC2 in the liver would be sufficient to increase hepatic gluconeogenesis and promote insulin resistance in peripheral tissues.

We found that selective expression of a constitutively active form of CRTC2 in liver for a period of up to 5 weeks increases the set point for circulating concentrations of glucose. This stable rise in blood glucose levels promotes compensatory increases in pancreatic islet mass and insulin secretion. The results point to an important role for hepatic CRTC2 in glucose homeostasis and in the development of hepatic insulin resistance.

Experimental Procedures

Adeno-associated Viruses (AAV) Strains and Propagation—Viruses were derived from pENN AAV TBG PI (an adeno-associated virus, serotype 8 with a TBG promoter), a generous gift from Dr. Morris Birnbaum at the University of Pennsylvania. Briefly, pENN AAV TBG PI was digested with enzymes Acc65I and SalI (New England Biolabs, Danvers, MA; #R0599 and #R0138). Meanwhile, a pcDNA3 construct expressing a FLAG-tagged mouse CRTC2 with mutations S171A and S275A was amplified by PCR (primers: GCCGGTACCATGACCATGGATTACAAAGATTACCAAGGAT, and GCCGTGACTAGGTGACAC-TATAGAATAGG) and then digested with Acc65I and SalI. The digested pENN AAV TBG PI was ligated with the FLAG.CRTC2AA PCR fragment and transformed in recombination-deficient Escherichia coli SURE cells (Agilent, Santa Clara, CA; #200238).

The resulting vectors (pENN AAV TBG PI and pENN AAV TBG PI CRTC2AA) were amplified in the Salk Institute Gene Transfer Targeting and Therapeutics Core. The amplified viruses are hereafter referred to as AAV.Empty and AAV.CRTC2AA.

Animals—Mice were housed in colony cages in a temperature-controlled environment under a 12 h light/dark cycle with free access to water and a standard Chow diet (Lab Diet 5001). ChIP studies were performed using 8–10-week-old C57BL/6J mice from Jackson Laboratories (Bar Harbor, ME; <000664>). Unless noted, other studies were performed using 8–12-week-old B6(Cg)-Tyr<sup>c<sup>-21/J</sup></sup> mice from Jackson Laboratories (<000058>). CRE-Luciferase mice were described previously (17).

Mice received daily IP injections of 75 mg streptozotocin (STZ)/kg body weight in a sodium citrate buffer for three consecutive days; controls receive buffer-only injections. Experiments were performed after 14 days after the initial injection.

Mice were injected retro-orbitally at 8–10 weeks with 10<sup>11</sup> genomic copies (gc) of AAV.Empty or AAV.CRTC2AA virus as described (18, 19). All mouse experiments were performed in accordance with the Salk Institute Institutional Animal Care and Use Committee.

Mouse Genotyping—Mouse genotypes for CRE-Luciferase were determined on tail biopsies using real-time PCR with specific probes designed for luciferase (Transnetyx, Cordova, TN).

In Vivo Analysis—Pyruvate tolerance was tested in 16-hour fasted conscious mice after a baseline tail blood glucose measurement, with an intraperitoneal injection of sodium pyruvate (2 g/kg body weight) followed by tail blood glucose measurements every 15–30 min for 2 h (12).

Whole body insulin sensitivity was measured using the insulin tolerance test (ITT). For this, an intraperitoneal injection of 1 unit of insulin (Humulin-R, Eli Lilly, Indianapolis, IN)/kg body weight was administered followed by tail blood glucose measurements every 15 min for 1 h. Muscle and adipose tissue specimens for determination of Akt phosphorylation (as a measure of insulin action), were fasted for 4 h and then administered an intraperitoneal injection of 1 unit of insulin/kg body weight as above, and sacrificed 10 min postinjection.

For determination of fasting blood glucose levels, mice were fasted overnight for 16 h with free access to water. Refed blood glucose values were determined after 4 h of free access to food. Glucose tolerance was measured by an intraperitoneal glucose tolerance test (IPGGT). Glucose (1 g/kg, ip) was administered followed by tail blood glucose measurements every 30 min for two hours. Continuous glucose monitoring was performed as previously described (20). Briefly, the sensor (Dexcom7 system, Dexcom, San Diego, CA) was inserted under the skin in anesthetized mice and calibrated twice daily based on blood glucose values determined with a LifeScan One Touch Ultra glucometer (Chesterbrook, PA).

For in vivo imaging of whole body luciferase activity, fasted and fed CRE-luciferase mice were anesthetized, treated with d-luciferin (150 mg/kg, IP) and underwent intra-vital imaging in an IVIS-100 instrument (Caliper Life Sciences) as previously described (17).

Tail blood glucose values were determined using a LifeScan One Touch Ultra glucometer. Serum insulin levels were measured using the Crystal Chem Ultra Sensitive Mouse Insulin ELISA (Downers Grove, IL; #90080).

Cell Culture and in vitro Analysis—Primary hepatocytes were derived from B6(Cg)-Tyr<sup>c<sup>-21/J</sup></sup> or CRE-Luc mice as previously described (18, 21). Hepatocytes expressing AAV.Empty or AAV.CRTC2AA were harvested from 8–10-week-old mice infected 3 days previously with AAV, and maintained in serum-free Medium 199 (Corning, Manassas, VA; #10-060). Hepatocytes were either stimulated with glucagon (100 nmol/liter, Sigma-Aldrich #G2044) or PBS as a negative control.

Gene Expression Analysis—Total cellular RNA from whole tissue or from primary hepatocytes was extracted using the RNaseasy kit (Qiagen, Valencia, CA; #74104), and cDNA was generated using the iScript select system (Bio-Rad #170-8840). cDNA was quantified via the LightCycler 480 instrument and 2× SYBR Green (Roche, Indianapolis, IA). Gene expression data are presented relative to parallel measured expression of housekeeping cDNA, for example RPL32 (L32).

Protein Analysis—Total protein from whole tissue or primary hepatocytes was extracted in RIPA buffer (50 mM TRIS pH 7.5; 150 mM sodium chloride; 1 mM EDTA; 50 mM sodium fluoride; 5 mM sodium pyrophosphate; 10 mM β-glycerophosphate; 1%
Nonidet P-40) containing 1 mM sodium orthovanadate; 1 mM dithiothreitol; 2 mM phenylmethanesulfonyl fluoride; 0.25% DOC (sodium deoxycholate); and 0.1% sodium dodecyl sulfate from Sigma. Proteins were quantified using the Bio-Rad Protein Assay Kit and separated using SDS-PAGE.

Immunoprecipitation—To 1 mg of tissue lysates (1 μg/μl) was added 40 μl of pre-cleared FLAG-M2 monoclonal antibody beads (Sigma #E3165); samples were incubated with rotation overnight at 4 °C. The supernatant was removed, and beads were washed five times with lysis buffer, eluted with 2× SDS loading buffer and analyzed via Western blot.

ChIP Assays—Livers were excised and immediately cross-linked in 1% formaldehyde while being shredded. Excessive formaldehyde was inactivated with glycine after 10 min of cross-linking. Using a hypotonic lysis buffer, nuclei were isolated and homogenized with a Dounce homogenizer. Resulting chromatin was sonicated 8 times for 10 s at 50% output, pre-cleared and incubated with the indicated antibodies overnight in the presence of phosphatase, protease, and HDAC inhibitors. Precipitated chromatin was purified, quantified by PCR (Lightcycler 480; Roche), and presented as a percentage of input chromatin.

Results

Acute Loss of Insulin Signaling Up-regulates CREB and CRTC2 Activities—CREB and CRTC2 are activated during fasting where they stimulate gluconeogenic gene expression following their recruitment to the promoter (Fig. 1). The CREB/CRTC2 pathway is inactivated during refeeding, leading to dismissal of CRTC2 from gluconeogenic promoters. We used the β cell toxin streptozotocin (STZ) to test the importance of insulin in regulating hepatic CREB/CRTC2 activity. Amounts of phosphorylated CREB were comparable between WT and STZ mice during fasting. By contrast with the refeeding-associated decrease in phospho-CREB amounts in controls, however, hepatic CREB phosphorylation remained elevated in STZ mice (Fig. 1a). Correspondingly, CRTC2 occupancy over gluconeogenic promoters was constitutively increased in STZ mice; and hepatic PCK1 and G6Pase mRNA amounts were also up-regulated (Fig. 1, b and c). These results demonstrate the importance of circulating insulin in attenuating CREB and CRTC2 activities during feeding.

CRTC2 Activation Triggers Down-regulation of FOXO1—We wondered whether constitutive activation of the CREB pathway in liver is sufficient to stimulate the gluconeogenic program. Based on the ability for adeno-associated viruses (AAVs) to be stably maintained as extra-chromosomal plasmids in infected cells, we prepared adeno-associated virus serotype 8 containing a Flag epitope-tagged CRTC2 cDNA with Serine-Alanine substitutions at inhibitory (Ser-171, Ser-275) sites. Mice were injected retro-orbitally with adeno-associated viruses expressing CRTC2S171,275AA (denoted AAV.CRTC2AA) or control virus (AAV.Empty) and followed thereafter for 36 days. Total hepatic CRTC2 protein amounts were increased by 35% in hepatocytes from AAV.CRTC2AA mice relative to controls (Fig. 3a). We detected AAV-encoded CRTC2 only in liver, and not in quadriceps muscles, white adipose tissue, or brown adipose tissue (Fig. 2a).

To evaluate effects of the CRTC2S171,275AA protein on hepatic CREB activity, we used transgenic mice expressing a CRE-Luciferase reporter (17). CREB reporter activity was robustly increased in AAV.CRTC2AA mice relative to controls under fasting as well as refeed conditions, when hepatic CREB activity is otherwise downregulated (p < 0.05, Fig. 2, b and c).
Supporting the notion that CREB activity is increased in animals expressing constitutively active CRTC2, mRNA amounts for G6Pase expression were higher in AAV.CRTC2AA compared with controls under fasting conditions (Fig. 2d). mRNA amounts for PCK1 and G6Pase were also up-regulated under fed conditions in AAV.CRTC2AA compared with control mice (Fig. 2d), demonstrating that induction of the CREB pathway in liver is indeed sufficient to stimulate the gluconeogenic program. As a result, feeding-associated suppression of PCK1 expression was significantly blunted in livers of AAV.CRTC2AA mice (49% reduction) compared with controls (74% reduction; Fig. 2d).

We considered that overexpression of active CRTC2 could trigger compensatory down-regulation of the forkhead transcription factor FOXO1. Indeed, amounts of Ser-256 phosphorylated and therefore inactive FOXO1 were substantially increased in livers of ad libitum fed AAV.CRTC2AA mice (Fig. 2e). Despite these increases, FOXO1 phosphorylation was not sufficient to block CREB/CRTC2 activities.

Constitutive Nuclear Localization of Phosphorylation-defective CRTC2—In keeping with results in liver, CRTC2 mRNA amounts were increased nearly 2-fold in AAV.CRTC2AA hepatocytes (Fig. 3a). Under basal conditions, protein amounts for dephosphorylated (active; lower band on immunoblot) CRTC2 were increased by 67% in AAV.CRTC2AA compared with control (Fig. 3a).

CRTC2 contains a number of phosphorylation sites in addition to Ser-171 and -275 that also contribute to its mobility (8, 10, 23). We performed immuno-cytochemical studies to visualize differences in nuclear accumulation between control and CRTC2AA expressing cells. Endogenous CRTC2 was primarily localized to the cytoplasm in the basal state; it shuttled to the nucleus in response to glucagon. By contrast, overexpressed CRTC2AA appeared nuclear under both basal and glucagon-stimulated conditions (Fig. 3b). These results suggest that AAV-encoded CRTC2AA is primarily expressed in hepatocytes, where it is constitutively nuclear-localized. Indeed, mRNA amounts for gluconeogenic genes (PCK1 and G6Pase) were up-regulated under basal conditions in hepatocytes from AAV-CRTC2AA mice. Exposure to glucagon further augmented PCK1 (p = 0.05) and G6Pase (p = 0.058) expression to a greater extent in AAV.CRTC2AA hepatocytes compared with controls (Fig. 3c).

Altered Glucose Set Point in Mice Expressing Constitutively Active CRTC2—Having seen that gluconeogenic gene expression is increased in isolated hepatocytes as well as livers of mice expressing the phosphorylation-defective CRTC2 polypeptide, we examined whether circulating blood glucose concentrations are correspondingly altered. Supporting this notion, AAV.CRTC2AA expressing mice had higher fasting blood glucose relative to control animals, under both short-term and overnight fasting conditions over a 5-week period (Fig. 4, a and b).

FIGURE 1. Hepatic CREB and CRTC2 are active under fasting conditions. a, immunoblot showing hepatic CREB (phosphorylated and total) under fasting and refed conditions in STZ treated and control mice. b, relative expression of PCK1 and G6Pase in livers of fasted and refed STZ and control animals. Expression levels are normalized to L32 and expressed as fold change to control fasted mice, n = 3. c, ChIP assay of CRTC2 over PCK1 and G6Pase promoters in livers from STZ or control mice under fasted and refed conditions; ChIP signals are normalized to total input.
Notably, *ad libitum* fed blood glucose concentrations were also increased in AAV.CRTC2AA mice (Fig. 4b).

To determine whether these differences were due to increases in hepatic gluconeogenesis, we performed a pyruvate tolerance test. Although glucose output from pyruvate was increased in the AAV.CRTC2AA animals, this difference appears to reflect primarily an increase in fasting blood glucose levels, rather than a change in hepatic gluconeogenesis (Fig. 4c).

Glucose clearance appeared comparable between AAV.CRTC2AA and control mice by intraperitoneal glucose tolerance testing. In keeping with results from pyruvate tolerance testing, the incremental area under the curve was comparable between both groups suggesting that the differences in circulating glucose concentration is primarily driven by the initial elevation in fasting blood glucose levels (Fig. 4d). Indeed, AAV.CRTC2AA mice had a persistent and fixed elevation in blood glucose levels by continuous glucose monitoring throughout an entire light-dark cycle (Fig. 4e), pointing to a change in the set point for circulating glucose concentrations.

**Hepatic Insulin Resistance and Steatosis in Mice Expressing Constitutively Active CRTC2**—We performed insulin tolerance testing to determine whether the elevations in fed and fasted glucose levels in AAV.CRTC2AA mice were associated with insulin resistance. Following insulin administration, blood glucose concentrations decreased in control animals but they remained elevated in AAV.CRTC2AA mice, demon-
demonstrating that AAV.CRTC2AA mice are indeed insulin resistant (Fig. 5a).

To determine if the observed increase in insulin resistance is also transmitted to peripheral tissues (muscle and fat), we measured effects of insulin on AKT phosphorylation in epididymal white adipose tissue (WAT) and quadriceps muscles. Phospho(Ser-473)AKT amounts appeared comparable between control and AAV.CRTC2AA mice under basal conditions and following insulin injection (Fig. 5b), indicating that the effects of CRTC2AA are likely confined to the liver. In keeping with the presence of hepatic insulin resistance, CRTC2AA mice had morphological evidence of hepatic steatosis (Fig. 5c). Hepatic triglycerides also appeared higher under ad libitum fed conditions, although they did not reach the level of statistical significance ($p = 0.06$, Fig. 5d).

Hepatic insulin resistance is often associated with increased serum insulin levels under ad libitum conditions (Fig. 6a) and compensatory increases in islet cell mass. Indeed, $\beta$-cell area was increased 36% in AAV.CRTC2AA mice, whereas $\alpha$-cell area was unchanged (Fig. 6, b and c). This increase was associated with an overall increase in islet area, and was due to the increase in islet cell number rather than cell size (Fig. 6d). Collectively, these results indicate that constitutive activation of the CREB pathway in liver is sufficient to promote insulin resistance and compensatory islet hyperplasia.

**Discussion**

Insulin resistance is a major risk factor for the development of type 2 diabetes, which is characterized by an inability for insulin to promote glucose uptake into muscle and to inhibit glucose production by the liver. Hepatic glucose output is elevated in type 2 diabetes, where it contributes to a number of complications including heart disease and peripheral neuropathy. We found that persistent activation of the CREB pathway in liver is sufficient to promote insulin resistance and compensatory islet hyperplasia.

Hepatic expression of AAV-encoded CRTC2AA triggered substantial increases in the activity of a hepatic CREB reporter.
that contains eight tandem CREB binding sites (17). By contrast, effects of CRTC2AA on gluconeogenic gene expression were more modest, likely reflecting in part compensatory increases in the AKT-mediated phosphorylation and inactivation of the forkhead transcription factor FOXO1 (Fig. 2). Hepatic expression of activated CRTC2 had no appreciable effect in other tissues, indicating that CREB/CRTC2 signaling primarily modulates hepatic insulin resistance.

Studies with STZ diabetic mice support an important role for insulin in attenuating CREB/CRTC activity during feeding. CRTC2 occupancy over gluconeogenic genes was increased in STZ diabetic mice primarily during feeding, when CRTC2 activity is otherwise down-regulated in response to insulin (21).

The chronic increases in CRTC2 activity and in gluconeogenic gene expression led to persistent elevations in fasting as

**FIGURE 4.** Chronic activation of the CREB pathway in liver increases fasting blood glucose concentrations. *a*, average overnight fasting blood glucose levels of mice infected with AAV.Empty or AAV.CRTC2AA over a 37-day period, n = 10. *b*, average blood glucose levels during ad-lib and fasting conditions; day 17–30, n = 10–20. *c*, pyruvate tolerance test on day 20 post virus injection, 2 g sodium pyruvate/kg mouse, n = 7. Right hand side of the figure shows calculated total area under the curve and incremental area under the curve. *d*, intraperitoneal glucose tolerance test on day 10 following viral infection, 1 g glucose/kg mouse, n = 10. Right, calculated total and incremental area under the curve. *e*, continuous glucose monitoring over a 24 h light/dark cycle with free access to food and water; n = 2 per group, 2 days of monitoring; average values shown. (*, p < 0.05; **, p < 0.005; ***, p < 0.0005 compared with AAV.Empty mice; data shown as mean ± S.E.).
well as ad libitum fed blood glucose levels. These observations indicate that the increase in gluconeogenesis is not suppressible and thus the baseline blood glucose of these animals has been “reset” to a higher level. Indeed, in continuous glucose monitoring studies, AAV.CRTC2AA mice had elevated blood glucose concentrations throughout the day/night cycle. As a result, mice expressing CRTC2AA are more insulin resistant due in part to the increase in hepatic gluconeogenesis. No direct measure of insulin resistance in liver was performed in our study, however; future work should confirm the apparent effects of CRTC2AA on hepatic glucose output.

Despite the presence of hepatic insulin resistance, the insulin response to the glucose challenge is appropriate to dispose of the glucose load at the same rate as in the control mice. This increase in the insulin response is consistent with the increase in β-cell area observed, which appears to be secondary to the hepatic insulin resistance.

The increase in islet area in AAV.CRTC2AA mice, which occurs due to hyperplasia rather than hypertrophy, appears to be limited to β cells and likely includes an increase in β-cell proliferation. Several mechanisms could underlie the expansion of β-cells in this setting. First, β-cell replication can be
driven by increased secretory demand placed upon the islet by dietary-fat-induced obesity and insulin resistance or chronic, mild hyperglycemia (24, 25). Additionally, secreted factors such as hepatocyte growth factor or glucagon-like peptide-1 can induce $\beta$-cell replication (26–28). It is also possible that the constitutively active expression of CRTC2 in the liver promotes transcription of a liver derived factor, which then promotes $\beta$-cell hyperplasia, such as that described by El Ouamari et al. in 2013 (29). Future studies should provide insight into this process.

We found that a persistent increase in CREB activity for a period of 5 weeks is sufficient to produce hepatic insulin resistance, leading to fasting hyperglycemia. Our studies also reveal that hepatic CREB signaling determines the homeostatic set point for plasma glucose concentrations. This persistent hyperglycemia was associated with a compensatory increase in $\beta$-cell area and an elevation of circulating insulin levels, thus preventing dramatic increases in fasting and post-prandial glucose. Future studies should reveal whether increases in circulating insulin concentrations promote fat accumulation in the liver, which is associated with insulin resistance (30–34).

**Author Contributions**—M. F. H. designed the study and performed the experiments, analyzed data, and wrote the manuscript. K. R. performed STZ studies and ChIP analysis of CRTC2 occupancy. S. M. performed the immunofluorescence of isolated hepatocytes and reviewed/edited the manuscript. M. O. H. assisted with the CGMS and reviewed/edited the manuscript. R. L. H. and S. E. K. analyzed and interpreted the data on islet morphology, and reviewed/edited the manuscript. M. M. designed the study, the experiments, analyzed data, and reviewed/edited the manuscript. All authors reviewed the results and approved the final version of the manuscript.

**Acknowledgments**—We thank Emilie Blanchet and Naomi Philips for technical help with the work reported in this manuscript.

**References**
1. Barthel, A., and Schmoll, D. (2003) Novel concepts in insulin regulation of hepatic gluconeogenesis. *Am. J. Physiol. Endocrinol. Metab.* **285**, E685–E692
2. Samuel, V. T., and Shulman, G. I. (2012) Mechanisms for Insulin Resistance: Common Threads and Missing Links. *Cell* **148**, 852–871
3. Saltiel, A. R., and Kahn, C. R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* **414**, 799–806

**FIGURE 6. Compensatory islet hyperplasia and hyperinsulinemia in mice expressing phosphorylation-defective CRTC2.**

*a*, serum insulin levels of ad-lib mice, $n = 5$. *b*, representative IF images of islets of mice, day 36 post viral infection. *c*, quantification of total islet area (left), and insulin and glucagon area (right) of islets from day 36 post viral infection, $n = 5$ mice, with an average of 17 islets/animal. *d*, quantification of total cell numbers and size of islets from day 36 post viral infection. (*, $p < 0.05$; **, $p < 0.005$ compared with AAV.Empty mice; data shown as mean ± S.E.)
Activation of CRTC2 Causes Hepatic Insulin Resistance

4. Biddinger, S. B., and Kahn, C. R. (2006) FROM MICE TO MEN: Insights into the Insulin Resistance Syndromes. *Annu. Rev. Physiol.* 68, 123–158

5. Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schütz, G., Yoon, C., Puisysger, P., Spiegelman, B. M., and Montminy, M. R. (2001) CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. *Nature* 413, 179–183

6. Hagiwara, M., Brindle, P. K., Haroutunian, A., Armstrong, R., Rivier, J., Vale, W., Tsien, R., and Montminy, M. R. (1993) Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. *Mol. Cell. Biol.* 13, 4852–4859

7. Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* 365, 855–859

8. Screaton, R. A., Conkright, M. D., Katoh, Y., Best, J. L., Canettieri, G., Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, M., and Montminy, M. R. (2004) The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. *Cell* 119, 61–74

9. Koo, S.-H., Flechon, L., Qi, L., Zhang, X., Screaton, R. A., Jefferis, S., Hedrick, S., Xu, W., Boussoeur, F., Brindle, P. K., Takemori, H., and Montminy, M. R. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. *Nature* 437, 1109–1111

10. Dentin, R., Hedrick, S., Xie, J., Yates, J., 3rd, and Montminy, M. R. (2008) Hepatic Glucose Sensing via the CREB Coactivator CRTC2. *Science* 319, 1402–1405

11. Wang, X. L., Suzuki, R., Lee, K., Tran, T., Gunton, J. E., Inoue, H., Tateno, K., Matsuoka, T., and Montminy, M. R. (2003) CREB facilitates gluconeogenesis through KAT2B- and WDR5-mediated epigenetic effects. *Proc. Natl. Acad. Sci. U.S.A.* 100, 3087–3092

12. Luo, Q., Lus, Q., Vite, K., Vite, K., Urday-Zaa, J. C., Urday-Zaa, J. C., Kumar, G. S., Tsai, W.-W., Talai, A., Mayo, K. E., Montminy, M. R., and Radhakrishnan, I. (2012) Mechanism of CREB recognition and coactivation by the CREB-regulated transcriptional coactivator CRTC2. *Proc. Natl. Acad. Sci. U.S.A.* 109, 20865–20870

13. Saberi, M., Bjelica, D., Schenk, S., Imamura, T., Bandyopadhyay, G. K., Li, P., Jadhar, V., Vargeese, C., Wang, W., Bowman, K., Zhang, Y., Polisky, B., and Olefsky, J. M. (2009) Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes. *J. Clin. Endocrinol. Metab.* 94, 428–439

14. Ravnkjaer, K., Hogan, M. F., Singh, P. K., Goebel, J. M., and Montminy, M. R. (2013) Liver-Derived Systemic Factors Drive β Cell Hyperplasia in a Mouse Model of Islet Amyloid. *Diabetes* 62, 372–379

15. Uebi, T., Tanaka, M., Horike, N., Hashimoto, Y. K., and Takemori, H. (2011) CREB functions as a calcium- and cAMP-sensitive coincidence detector. *Cell* 144, 23. Uebi, T., Tamura, M., Horike, N., Hashimoto, Y. K., and Takemori, H. (2011) CREB functions as a calcium- and cAMP-sensitive coincidence detector. *Cell* 144, 23

16. Solomon, J. M., and Montminy, M. R. (2005) CREB-regulated transcriptional coactivator CRTC2. *Cell* 122, 1226–1232

17. Ahima, R. S., Ueki, K., Kahn, C. R., and Birnbaum, M. J. (2012) Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. *Nature* 485, 449, 349–457

18. Qatanani, M., and Lazar, M. A. (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. *Genes Dev.* 21, 1443–1455

19. Hardy, O. T., Czech, M. P., and Corvera, S. (2012) What causes the insulin resistance underlying obesity? *Curr. Opin. Endocrinol. Diab. Obst.* 19, 81–87

20. Nagle, C. A., Klett, E. L., and Coleman, R. A. (2009) Hepatic triacylglycerol accumulation and insulin resistance. *J. Lipid Res.* 50, S74–S79